A PYMNTS Company

US: Mylan agrees to settle with DOJ for $465 million over EpiPens

By  |  October 9, 2016

The company announced Friday it had agreed to a $465 million settlement with the US Department of Justice over how it classified its EpiPens to pay lower rebates to Medicaid and Medicare.

In a statement, the company said the terms of the settlement don’t provide any finding for wrongdoing on Mylan’s apart.

“This agreement is another important step in Mylan’s efforts to move forward and bring resolution to all EpiPen Auto-Injector related matters,” said Mylan CEO Heather Bresch in a statement.

“The agreement is in addition to the significant steps Mylan has taken in relation to EpiPen Auto-Injector over the past several weeks, including the unprecedented, pending launch of a generic version of EpiPen Auto-Injector and expansion of our patient access programs for this product.”

“The Justice Department does not confirm or deny the existence of an investigation,” wrote Department of Justice spokeswoman Nicole A. Navas in an email to NBC News.

Full Content: NBC News

Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.